AAN 2022
Welcome to the Novartis microsite for AAN, the world’s premier neurology meeting.
This year, Novartis is proud to present the latest research and findings in multiple sclerosis
Ofatumumab
![](/sites/medhub.com.au/files/long_term_safety.png)
[P5.004] Long-term safety of ofatumumab in patients with relapsing multiple sclerosis
Hauser S. et.al
![](/sites/medhub.com.au/files/efficacy.png)
[P5.004] Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis
Hauser S. et.al
![](/sites/medhub.com.au/files/injection.png)
[P7.011] Injection-related reactions with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: Data from clinical studies and post marketing experience
Kramer J. et.al
Siponimod
![](/sites/medhub.com.au/files/cognitive_processing.png)
[P5.006] Cognitive processing speed predicts disease progression in secondary progressive multiple sclerosis: Post hoc analysis from the EXPAND study
Penner I. et.al
![](/sites/medhub.com.au/files/estimating.png)
[P16.008] Estimating the profile of responders to treatment in the phase 3EXPAND trial: Do different patients show benefits on different outcomes?
Bovis F. et.al
![](/sites/medhub.com.au/files/discordance.png)
[P10.004] Discordance between neurologists and people with multiple sclerosis on the perception of the presence and burden of cognitive impairment -
Penner I. et.al